Amgen Inc. (AMGN)

194.09
2.65 1.38
NASDAQ : Health Technology
Prev Close 191.44
Open 192.52
Day Low/High 188.19 / 194.79
52 Wk Low/High 163.31 / 210.19
Volume 2.72M
Avg Volume 2.88M
Exchange NASDAQ
Shares Outstanding 637.22M
Market Cap 121.99B
EPS 2.70
P/E Ratio 49.85
Div & Yield 5.28 (2.65%)

Latest News

Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend

Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend

THOUSAND OAKS, Calif., Dec.

Markets Closed Wednesday/Amgen Update

We see multiple ways for AMGN to win.

Video: Jim's Daily Rundown for Tuesday

Jim discusses Amazon's challenge against freight transportation companies, Apple, why he is excited about a new study from Amgen, CVS Health, Nvidia, and more!

The Real Money Post-Industrial Average Has Jumped 11% So Far This Year

The Real Money Post-Industrial Average Has Jumped 11% So Far This Year

For the month of November RMPIA climbed 1.2% month over month.

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018

Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia

Here's What You Need to Know About the U.S.-China Trade Truce

Market sentiment has certainly improved from this weekend's events.

Amgen To Present At The Citi Global Healthcare Conference

Amgen To Present At The Citi Global Healthcare Conference

THOUSAND OAKS, Calif., Dec.

Weekly Roundup

The market responded favorably after Fed Chair Jerome Powell portrayed a more dovish stance on interest rates.

Amgen To Webcast Investor Call At ASH 2018

Amgen To Webcast Investor Call At ASH 2018

THOUSAND OAKS, Calif., Nov.

Amgen To Present At The Piper Jaffray And Evercore ISI Healthcare Conferences

Amgen To Present At The Piper Jaffray And Evercore ISI Healthcare Conferences

THOUSAND OAKS, Calif., Nov.

Here's Why We Were Buyers on a Day Like Today

We bought today what the market sold the hardest such as high-multiple cloud/software technology stocks like Salesforce.com and Palo Alto Networks.

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer pushes higher on price increases.

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.

Weekly Roundup

Markets endured another volatile week.

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

First and Only EU Marketing Authorization Application to Include Presence of Minimal Residual Disease

Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018

Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018

Additional Data Analyzing Treatment Patterns in the United States Shows Underutilization of LDL-C Lowering Treatments in At-Risk Patients and Need for Improved Patient Awareness of Treatment Goals

Amgen Is Showing Independent Strength in a Bullish Sign for the Future

Amgen Is Showing Independent Strength in a Bullish Sign for the Future

Investors should continue to hold Amgen.

Amgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires

Amgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires

New Pledge is in Addition to $250,000 Contribution to Ventura County Community Foundation's Conejo Valley Victims Fund

Your Game Plan: Cramer's 'Mad Money' Recap (Friday 11/9/18)

Your Game Plan: Cramer's 'Mad Money' Recap (Friday 11/9/18)

Jim Cramer says the Fed is overreacting and he isn't worried about oil prices. Here's your game plan for next week.

Weekly Roundup

Markets had another volatile week as trade tensions crossed currents with a U.S. midterm election that was closer than many had predicted.

Video: Jim's Daily Rundown for Thursday

Jim discusses Aimovig and Amgen, Anadarko and Schlumberger, the Federal Reserve, Disney ahead of earnings, and more!

Reviewing Some Winners After the Election Results

We think defense stocks, among other sectors, can rally.

Drug Stocks Climb as Investors Digest Midterm Election Results

Drug Stocks Climb as Investors Digest Midterm Election Results

A split Congress is the best-case scenario for the drug industry, several analysts said.

Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018

Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018

Additional Analyses of Real-World Data Will Explore Treatment Utilization and Understanding of Treatment Goals in Patients at High Risk for Cardiovascular Events

Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease

Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease

Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714

Microsoft, Ross Stores, Pitney Bowes: 'Mad Money' Lightning Round

Microsoft, Ross Stores, Pitney Bowes: 'Mad Money' Lightning Round

Jim Cramer takes a look at Microsoft, Ross Stores, Pitney Bowes, Alnylam Pharmaceuticals, Golar LNG, ResMed and more.

Market Whiplash: Cramer's 'Mad Money' Recap (Friday 11/2/18)

Market Whiplash: Cramer's 'Mad Money' Recap (Friday 11/2/18)

Jim Cramer breaks down the day's roller-coaster action amid confusing news. Plus, he's got your game plan for next week.

TheStreet Quant Rating: B- (Buy)